ZEN Study

A prospective, multicenter, phase III, randomized, non-inferiority trial comparing zoledronic acid administered every 12 weeks vs every 4 weeks in Non Small Cell Lung Cancer (NSCLC) patients with metastatic bone disease.

Flow chart of the ZEN Study

A prospective, multicenter, phase III, randomized, non-inferiority trial comparing zoledronic acid administered every 12 weeks vs every 4 weeks in Non Small Cell Lung Cancer (NSCLC) patients with metastatic bone disease.


image